Opinion|Videos|August 16, 2024

Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

Author(s)Benjamin H. Lowentritt, MD, FACS, Brian Richardson, MD, Angelo A. Baccala, MD

The panel emphasizes the crucial need for swift biomarker and genetic testing to facilitate timely and effective patient care in prostate cancer management.

Episodes in this series

A panel of 4 experts on prostate cancer

EP. 1 Overview of Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 2 Challenges of PSA as a Diagnostic Biomarker

A panel of 4 experts on prostate cancer

EP. 3 Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

A panel of 4 experts on prostate cancer

EP. 4 Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

A panel of 4 experts on prostate cancer

EP. 5 High Risk Populations in the Development of Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 6 Risk Stratification in Prostate Cancer Patients

A panel of 4 experts on prostate cancer

EP. 7 Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

A panel of 4 experts on prostate cancer

EP. 8 Influences and Challenges of Biomarkers on Treatment Selection

A panel of 4 experts on prostate cancer

EP. 9 Efficacy of Biomarker Test Results

A panel of 4 experts on prostate cancer

EP. 10 Biomarker Use in Patients on Active Surveillance

A panel of 4 experts on prostate cancer

EP. 11 Use of Molecular Biomarkers Tests

A panel of 4 experts on prostate cancer

EP. 12 Integrating Biomarker Testing Into the Patient Care Journey

A panel of 4 experts on prostate cancer

EP. 13 AI and the Future of Biomarkers in Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 14 Current Advancements in Biomarker Research

A panel of 4 experts on prostate cancer

EP. 15 Unmet Needs and Treatment Gaps in Prostate Cancer

EP. 16 Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP. 16 Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP. 17 Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP. 17 Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP. 18 Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP. 18 Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP. 19 Paul Sieber, MD, on the future of genetic testing in prostate cancer

EP. 19 Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

What is the role for biomarker and genetic testing in diagnosing prostate cancer?
- When during the disease course do you test for biomarkers?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

ByAdam B. Weiner, MD,Tyler Seibert, MD, PhD

August 21st 2026

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

ByMary Dunn, MSN, NP-C, OCN, RN

August 20th 2026

SBRT improves multiple quality of life domains but not DFS vs MH-IMRT

ByHannah Clarke

August 18th 2026

Active surveillance use for low-risk prostate cancer reaches 93% in VA system

ByHannah Clarke

August 14th 2026

Focal therapy for prostate cancer frequently used outside guideline-supported groups

ByHannah Clarke

August 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care